RankingsPricing
  1. US-listed companies
  2. Kiniksa Pharmaceuticals International, plc
  3. Raw

Kiniksa Pharmaceuticals International, plcKNSA

Market cap
$6.1B
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023		Dec 31,
2024
Product----123233417
Collaboration----98376
Revenue---39220270423
Product----2333-
Collaboration----2457-
Cost of goods sold---9--61
Collaboration expenses------128
Research and development87135112996576112
Selling, general and administrative---8698129168
Total operating expenses---195210295469
Income (loss) from operations-108-170-157-15710-25-46
Other income----199
Income (loss) before income taxes-103-164-156-15711-17-36
Benefit (provision) for income taxes-0-251-172-317
Net income (loss)-103-162-161-15818314-43
Earnings Per Share, Basic----2.32.640.2-0.6
Earnings Per Share, Diluted----2.32.60.2-0.6
Net income (loss)-103-162-161-15818314-43
Unrealized gain (loss) on short-term investments and currency translation adjustments, net of tax-00-0-00-0-0
Total other comprehensive income (loss)-00-0-00-0-0
Total comprehensive income (loss)-103-162-161-15818314-43